Loading & Targeting EDV’s
Drug or siRNA or miRNA packaging in EDV™ nanocells
A single 400nm EDV™ can be packed with up to 1 million molecules of an anticancer drug such as Doxorubicin or the extremely potent derivative of nemorubicin, PNU159682, which is unable to be used systemically as a clinical chemotherapeutic due to its severe toxicity. Animal and human studies have provided positive safety and efficacy data.
In addition, regulatory genetic molecules (siRNA/miRNA) can be loaded in therapeutically significant concentrations as demonstrated in animal and human trials.
EDV loaded with drug,
siRNA or miRNA
Specific Targeting of EDVs to tumours
Payload-packaged EDV™ is coated with a bispecific antibody which attaches through antibody-antigen interaction to the EDV™ at one end and has specificity to cancer cells on the other end. The tumor targeting antibody can be changed depending on the type of cancer.